Enduring Material

For physicians, there is new maintenance of certification (MOC) requirements. This self-assessment module helps you meet these new standards.

As part of recertification requirements, physicians must now participate in Maintenance of Certification Program (MOC) activities like this one to cultivate a focus on lifelong learning and competency throughout one’s profession. This module helps you hone in on clinical and practice management skills that are central to quality patient care and improved outcomes for patients with substance use disorders.

The American Board of Psychiatry and Neurology (ABPN) has reviewed the Kaufman Psychiatry Self-Assessment Module and has approved this program as part of a comprehensive self-assessment program, which is mandated by the American Board of Medical Specialties (ABMS) as a necessary component of maintenance of certification.

This is a 200-question exam.

Target Audience: The target audience for this module is psychiatrists.

Special thanks to our additional question writers and editors:
Ian Johnson, MD
Austin Katona, MD
April Malikowski, MD
Eric Nelson, MD
Julia Rutenberg, MD

Disclaimer: The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented for this CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine-Montefiore Medical Center. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Merrill Herman, MD, David Kaufman, MD, John Kenny, MD, Stephen Nicolson, MD, Bruce J. Schwartz, MD, and Andrea Weiss, MD have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Ian Johnson, MD, Austin Katona, MD, April Malikowski, MD, Eric Nelson, MD, Julia Rutenberg, MD have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.